The GLP is committed to full transparency. Download and review our 2019 Annual Report

FDA critical of stem-cell firm

| | July 3, 2012

The Sugar Land company involved in Gov. Rick Perry‘s unlicensed adult stem-cell procedure is rife with basic manufacturing problems, according to the U.S. Food and Drug Administration.

View the original article here: FDA critical of stem-cell firm – MySanAntonio

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend